Investor Presentaiton
SELECT TRIALS - EARLY PHASE DIABETES AND OBESITY (CONT.)
Lilly
Molecule
Study
Indication*
Title
Phase Patients
DACRA QW II NCT05380323
Obesity
A Study of LY3541105 in Healthy and Overweight
Participants
1
160
GIPR Agonist
LA II
NCT05407961
Diabetes
Mellitus,
Type 2
A Study of LY3532226 in Participants With Type 2
Diabetes Mellitus
1
92
Primary Outcome**
Number of Participants with One or More Treatment
Emergent Adverse Events (TEAEs) and Serious Adverse
Event(s) (SAEs) Considered by the Investigator to be
Related to Study Drug Administration
Part A: Number of Participants with One or More
Treatment Emergent Adverse Events (TEAEs) and Serious
Adverse Event(s) (SAEs) Considered by the Investigator to
Primary
Completion
Completion
Oct 2023 Oct 2023
Oct 2023 Oct 2023
Nisotirostide
Diabetes
(PYY Analog NCT05377333
Agonist)
Mellitus,
Type 2
A Study of LY3457263 Alone and in Combination With
Dulaglutide (LY2189265) in Participants With Type 2
Diabetes
1
86
be Related to Study Drug Administration
Number of Participants with One or More Treatment
Emergent Adverse Events (TEAEs) and Serious Adverse
Event(s) (SAEs) Considered by the Investigator to be
Nov 2023 Nov 2023
Amylin
Agonist LA
NCT05295940
Obesity
A Study of LY3841136 in Healthy and Overweight
Participants
1
160
Related to Study Drug Administration
Number of Participants with One or More Treatment
Emergent Adverse Events (TEAEs) and Serious Adverse
Event(s) (SAEs) Considered by the Investigator to be
Jan 2024 Jan 2024
* Molecule may have multiple indications
** Trial may have additional primary and other secondary outcomes
Not for promotional use
Related to Study Drug Administration
Source: clinicaltrials.gov, July 14, 2023
2023 Q2 EARNINGS
52
62View entire presentation